These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38479009)

  • 1. Systematic Review of Neoadjuvant Immunotherapy for Mismatch Repair Deficient Locally Advanced Colon Cancer: An Emerging Strategy.
    Loria A; Ammann AM; Olowokure OO; Paquette IM; Justiniano CF
    Dis Colon Rectum; 2024 Jun; 67(6):762-771. PubMed ID: 38479009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
    Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer.
    Xiao BY; Zhang X; Cao TY; Li DD; Jiang W; Kong LH; Tang JH; Han K; Zhang CZ; Mei WJ; Xiao J; Pan ZZ; Li YF; Zhang XS; Ding PR
    J Natl Compr Canc Netw; 2023 Jan; 21(1):60-66.e5. PubMed ID: 36630898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A locally advanced colon cancer patient with Muir-Torre syndrome obtains durable response to neoadjuvant and adjuvant immunotherapy.
    Guo Z; Cai Y; Yin W; Huang J
    Tumori; 2023 Dec; 109(6):NP27-NP31. PubMed ID: 37880978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series.
    Pan T; Yang H; Wang WY; Rui YY; Deng ZJ; Chen YC; Liu C; Hu H
    Clin Colorectal Cancer; 2024 Mar; 23(1):104-110. PubMed ID: 38336555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
    Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
    Front Immunol; 2022; 13():913483. PubMed ID: 35958603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
    Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
    Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer.
    Li Y; Zhang W; Du J; Hu J; Hu R; Zeng Z; Jin-Si-Han EE; Lian S; Wang H; Li Y; Pan Z; Feng C; Zhang X; Lu Z
    Target Oncol; 2024 Jul; 19(4):601-610. PubMed ID: 38691294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research Perspective on: Systematic Review of Neoadjuvant Immunotherapy for Mismatch Repair-Deficient Locally Advanced Colon Cancer: An Emerging Strategy.
    Liska D
    Dis Colon Rectum; 2024 Jun; 67(6):772. PubMed ID: 38452372
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
    Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laparoscopic complete mesocolic excision after neoadjuvant immunotherapy for advanced microsatellite instability high/deficient mismatch repair transverse colon cancer - a video vignette.
    Lian Y; Duan X; Hu S; Han M; Yuan W
    Colorectal Dis; 2024 May; 26(5):1093-1094. PubMed ID: 38553801
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcome of Patients With Early-Stage Mismatch Repair Deficient Colorectal Cancer Receiving Neoadjuvant Immunotherapy: A Systematic Review.
    Chakrabarti S; Grewal US; Vora KB; Parikh AR; Almader-Douglas D; Mahipal A; Sonbol MBB
    JCO Precis Oncol; 2023 Aug; 7():e2300182. PubMed ID: 37595183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant envafolimab in a patient with MSI-H/dMMR colon cancer: a case report and literature review.
    Chen Z; Zhou J; Chen W; Wu T; Lian K; Shen T
    Immunotherapy; 2024; 16(10):649-657. PubMed ID: 39259508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bM0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study.
    Han K; Tang JH; Liao LE; Jiang W; Sui QQ; Xiao BY; Li WR; Hong ZG; Li Y; Kong LH; Li DD; Zhang XS; Pan ZZ; Steele SR; Ding PR
    Dis Colon Rectum; 2023 Oct; 66(10):e996-e1005. PubMed ID: 35485833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
    Chalabi M; Fanchi LF; Dijkstra KK; Van den Berg JG; Aalbers AG; Sikorska K; Lopez-Yurda M; Grootscholten C; Beets GL; Snaebjornsson P; Maas M; Mertz M; Veninga V; Bounova G; Broeks A; Beets-Tan RG; de Wijkerslooth TR; van Lent AU; Marsman HA; Nuijten E; Kok NF; Kuiper M; Verbeek WH; Kok M; Van Leerdam ME; Schumacher TN; Voest EE; Haanen JB
    Nat Med; 2020 Apr; 26(4):566-576. PubMed ID: 32251400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.
    Chalabi M; Verschoor YL; Tan PB; Balduzzi S; Van Lent AU; Grootscholten C; Dokter S; Büller NV; Grotenhuis BA; Kuhlmann K; Burger JW; Huibregtse IL; Aukema TS; Hendriks ER; Oosterling SJ; Snaebjornsson P; Voest EE; Wessels LF; Beets-Tan RG; Van Leerdam ME; Schumacher TN; van den Berg JG; Beets GL; Haanen JB
    N Engl J Med; 2024 Jun; 390(21):1949-1958. PubMed ID: 38838311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Immunotherapy in Microsatellite-Instability High Nonmetastatic Colorectal Cancer: A Single-institute Experience and Review of the Literature.
    Kinney RE; Khalil M
    Clin Colorectal Cancer; 2021 Jun; 20(2):e109-e112. PubMed ID: 33722513
    [No Abstract]   [Full Text] [Related]  

  • 18. [Neoadjuvant immunotherapy for colorectal cancer].
    Pei JP; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):58-67. PubMed ID: 36650001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
    Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171
    [No Abstract]   [Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.